Halozyme Therapeutics (HALO) Stock Price & Analysis

HALO$100.27-0.40 -0.40%
BiotechnologyLarge CapValue StockGrowth StockHigh Quality
Compare
Market cap$11.43BEnterprise value$16.78BRevenue (TTM)$1.66BMarket positionTop 25%

Score

69
Bullish
Value
61
Quality
85
Growth
62

AI Analysis

Snapshot

Halozyme Therapeutics looks like a quality compounder first — Quality 85/100 and an overall 69/100. Under the hood: P/E 37.0, rich vs its own history, plus revenue compounding ~29% annually over recent years.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

61
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

62
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

85
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Halozyme Therapeutics, Inc. (HALO) last printed $100.27. Equity value is $11.43B. Trailing earnings multiple 27.64. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$146.69M$316.61M$151.86M$195.99M$267.59M$443.31M$660.12M$829.25M$1.02B$1.4B

About

Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.

Halozyme Therapeutics (HALO) Stock Price & Analysis

HALO price $100.27 -0.40 -0.40%

Ticker
HALO
Price
$100.27
Change
-0.40 -0.40%
Market cap
$11.43B
P/E
27.64
Forward P/E
9.97
Dividend yield
0.00%
Beta
0.90
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
69
Value
61
Quality
85
Growth
62

Stocklytics score rationale: value 61, quality 85, growth 62.

AI Score 70. Halozyme Therapeutics, Inc. has a strong gross profit margin of approximately 82.4% and a healthy current ratio of 2.7, indicating solid financial health

Insights · Forecast · Financials · Learn

Stocklytics home · Screener